Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pheniramine is a first-generation antihistamine in the alkylamine class used to treat allergic conditions such as allergic rhinitis (hay fever), urticaria (hives), pruritus (itching), and conjunctivitis. It acts primarily as an antagonist and inverse agonist at the histamine H1 receptor, blocking the effects of histamine released during allergic reactions. This reduces symptoms like itching, redness, swelling (edema), sneezing, and runny nose. Pheniramine also has anticholinergic properties that contribute to its sedative effects. It is available in oral formulations as well as topical preparations for ophthalmic use and is often found in combination with other drugs for cold or allergy relief[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pheniramine.